BTYNB IMP1 Inhibitor |
| Catalog No.GC42986 |
BTYNB IMP1 Inhibitor is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC50=5 μM). BTYNB IMP1 Inhibitor exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB IMP1 Inhibitor can be used for cancer research.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 304456-62-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). [1] It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.
Reference:
[1]. Mahapatra, L., Andruska, N., Mao, C., et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10(5), 818-827 (2017).
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *